Demystifying Stem Cell Transplant for Multiple Myeloma Treatment


Manage episode 188821032 series 1143960
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
In 2017 stem cell transplants remain a key option for treatment of eligible multiple myeloma patients, and in majority of patients it is done as a part of frontline therapy. Research shows that stem cell transplants significantly increases the amount of time, for which a patient has their disease under control. How safe are transplants? Who is eligible to get one? What are the side effects and how can patients tackle them? The myeloma panel is talking to Dr. Rafael Fonseca for answers to these and more on the latest developments in stem cell transplant technology in multiple myeloma treatment. Dr. Fonseca is currently deputy director, Mayo Clinic Cancer Center, Getz Family Professor of Cancer and professor of medicine, Mayo Clinic College of Medicine, as well as site director, hematological malignancies, Mayo Clinic, Scottsdale, Arizona. Dr. Fonseca is a fellow of the International Society of Hematology and is board certified in internal medicine, medical oncology, and hematology. In addition, he holds professional memberships in the American Association of Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and the Mexican Society of Internal Medicine, among others. Dr. Fonseca is a reviewer for numerous journals including American Journal of Hematology, American Journal of Medicine, Blood, British Journal of Haematology, Circulation, Hematologica, International Journal of Cancer, Journal of Clinical Oncology, Leukemia, New England Journal of Medicine, and is on the editorial board of Molecular Cancer Therapeutics, and Leukemia. He has written more than 100 peer-reviewed articles, book chapters, and abstracts. Dr. Fonseca has developed an expertise in the management of plasma cell disorders. His clinical practice is primarily composed of patients with multiple myeloma, primary amyloidosis, and monoclonal gammopathy.

165 episodes available. A new episode about every 20 days averaging 60 mins duration .